Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer

Presence of active autoimmune disease, or long-term requirement for immunosuppressive agents;

Prior treatment with immune checkpoint inhibitors;

Concurrent persistent or active infections, such as hepatitis B, hepatitis C, etc.;

Concurrent severe dysfunction of vital organs including heart, lung, liver and kidney: alanine aminotransferase/aspartate aminotransferase elevated more than 3 times the upper limit of normal (ULN) and unresponsive to liver-protective therapy; serum creatinine ≥1.5 × ULN; abnormal thyroid function; history of heart failure, unstable angina pectoris, severe arrhythmia, myocarditis, interstitial lung disease, non-infectious pneumonitis or active pulmonary infection, etc.;